ArticleACS medicinal chemistry letters2019
Novel Sustainable-by-Design HDAC Inhibitors for the Treatment of Alzheimer's Disease.
Article in ACS medicinal chemistry letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Cashew-Derived Flavonoids Modulate the Th1/Th2 Balance at Peyer's Patches via a C-Ring Oxidation-Dependent Molecular Switch.Journal of food science · 2026Article
- Epigenetic Dysregulation in Neurodegeneration: The Role of Histone Deacetylases and Emerging Inhibitor Strategies.Biomolecules · 2026Review
- Derivatives of the Cashew Nut Shell Liquid as Ligands ofACS omega · 2025Article
- Epigenetic regulation of pathogenicity in fungi.Current genetics · 2025Review
- Medicinal Chemistry: A Key Driver in Achieving the Global Sustainable Development Goals.Journal of medicinal chemistry · 2025Review
- Histone Deacetylase Inhibition in Alzheimer's Disease: Molecular Mechanisms, Therapeutic Potential, and Future Perspectives.Current topics in medicinal chemistry · 2025Review
- Comprehensive medicinal chemistry survey highlights a portfolio of lead molecules for Alzheimer's disease therapy.Frontiers in chemistry · 2025Review
- Histone deacetylases: Regulation of vascular homeostasis via endothelial cells and vascular smooth muscle cells and the role in vascular pathogenesis.Genes & diseases · 2024Review
- Benign-by-Design SAHA Analogues for Human and Animal Vector-Borne Parasitic Diseases.ACS medicinal chemistry letters · 2024Article
- Review
- Histone Deacetylase (HDAC) Inhibitors for the Treatment of Schistosomiasis.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Cashew Nut Shell Liquid (CNSL) as a Source of Drugs for Alzheimer's Disease.Molecules (Basel, Switzerland) · 2021Review
- Discovery of sustainable drugs for Alzheimer's disease: cardanol-derived cholinesterase inhibitors with antioxidant and anti-amyloid properties.RSC medicinal chemistry · 2021Article
- Sustainable Drug Discovery of Multi-Target-Directed Ligands for Alzheimer's Disease.Journal of medicinal chemistry · 2021Article
- Epigenetics and Communication Mechanisms in Microglia Activation with a View on Technological Approaches.Biomolecules · 2021Review
- The Application of Nanotechnology for the Diagnosis and Treatment of Brain Diseases and Disorders.Frontiers in bioengineering and biotechnology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) represents a global problem, with an estimation of the majority of dementia patients in low- and middle-income countries by 2050. Thus, the development of sustainable drugs has attracted much attention in recent years. In light of this, taking inspiration from the HDAC inhibitor vorinostat (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.